Shots:

• The P-II study will evaluate MK-5890 + Keytruda (pembrolizumab) in patients with sq. and non-sq. NSCLC prior treated with anti-PD-L1 therapy. The study is the part of pembrolizumab umbrella master protocol (MK-3475-U01)
• In 2014- Merck signed WW license agreement with Aduro to develop & commercialize MK-5890- under which Aduro received $10M as development milestones on the initiation of P-II study of MK-5890
• Aduro’s MK-5890 is an anti-CD27 agonist- demonstrated a T-cell enhancement in combination with an immune checkpoint inhibitor and showed complete tumor eradication in its preclinical studies

Click here ­to­ read full press release/ article 

Ref: Aduro | Image: Merck